» Articles » PMID: 23558166

Case-control Study of Birth Characteristics and the Risk of Hepatoblastoma

Overview
Publisher Elsevier
Specialties Oncology
Public Health
Date 2013 Apr 6
PMID 23558166
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatoblastoma is a malignant embryonal tumor typically diagnosed in children younger than five years of age. Little is known on hepatoblastoma etiology.

Methods: We matched California Cancer Registry records of hepatoblastomas diagnosed in children younger than age 6 from 1988 to 2007 to birth records using a probabilistic record linkage program, yielding 261 cases. Controls (n=218,277), frequency matched by birth year to all cancer cases in California for the same time period, were randomly selected from California birth records. We examined demographic and socioeconomic information, birth characteristics, pregnancy history, complications in pregnancy, labor and delivery, and abnormal conditions and clinical procedures relating to the newborn, with study data taken from birth certificates.

Results: We observed increased risks for hepatoblastoma among children with low [1500-2499 g, Odds Ratio (OR)=2.02, 95% confidence interval (CI) 1.29-3.15] and very low birthweight (<1500 g, OR=15.4, 95% CI 10.7-22.3), preterm birth <33 weeks (OR=7.27, 95% CI 5.00, 10.6), small size for gestational age (OR=1.75, 95% CI 1.25-2.45), and with multiple birth pregnancies (OR=2.52, 95% CI 1.54-4.14). We observed a number of pregnancy and labor complications to be related to hepatoblastoma, including preeclampsia, premature labor, fetal distress, and congenital anomalies.

Conclusion: These findings confirm previously reported associations with low birthweight and preeclampsia. The relation with multiple birth pregnancies has been previously reported and may indicate a relation to infertility treatments.

Citing Articles

Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.

Guo C, Liu Z, Zhang X, Zhao S, Fan H, Wang H Hepatol Int. 2024; 19(1):156-165.

PMID: 39580764 DOI: 10.1007/s12072-024-10750-x.


Maternal illnesses during pregnancy and the risk of childhood cancer: A medical-record based analysis (UKCCS).

Bonaventure A, Simpson J, Kane E, Roman E Int J Cancer. 2024; 156(5):920-929.

PMID: 39535336 PMC: 11701404. DOI: 10.1002/ijc.35166.


IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma.

Li L, Wu Y, Huang H, Yong J, Lv Z, Zhou Y J Cancer Res Clin Oncol. 2024; 150(8):377.

PMID: 39085725 PMC: 11291533. DOI: 10.1007/s00432-024-05858-4.


Hepatoblastoma with neonatal necrotizing enterocolitis: Two case reports.

He S, Wang X, Duan C, Zhao W, Jiang C, Zhang S Cancer Innov. 2023; 2(6):532-536.

PMID: 38125764 PMC: 10730001. DOI: 10.1002/cai2.86.


Preeclampsia, antihypertensive medication use in pregnancy and risk of childhood cancer in offspring.

Askins L, Orimoloye H, Deng C, Hansen J, Olsen J, Ritz B Cancer Causes Control. 2023; 35(1):43-53.

PMID: 37535154 PMC: 10764520. DOI: 10.1007/s10552-023-01745-4.


References
1.
Hughes L, Michels V . Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992; 43(6):1023-5. DOI: 10.1002/ajmg.1320430621. View

2.
Alexander G, Himes J, Kaufman R, Mor J, Kogan M . A United States national reference for fetal growth. Obstet Gynecol. 1996; 87(2):163-8. DOI: 10.1016/0029-7844(95)00386-X. View

3.
Narod S, Hawkins M, Robertson C, Stiller C . Congenital anomalies and childhood cancer in Great Britain. Am J Hum Genet. 1997; 60(3):474-85. PMC: 1712528. View

4.
Ansell P, Mitchell C, Roman E, Simpson J, Birch J, Eden T . Relationships between perinatal and maternal characteristics and hepatoblastoma: a report from the UKCCS. Eur J Cancer. 2005; 41(5):741-8. DOI: 10.1016/j.ejca.2004.10.024. View

5.
DeBaun M, Tucker M . Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998; 132(3 Pt 1):398-400. DOI: 10.1016/s0022-3476(98)70008-3. View